Claudin is a promising biomarker of intestinal wall permeability
https://doi.org/10.31146/2949-4664-apps-2-2-76-79
Abstract
To date, sufficient information is available on changes in the levels of tight contact proteins (TCPs) in various diseases. Of greatest interest is the study of claudin due to numerous studies confirming the important role of this protein in the development of pathologies. Deafness, behavioural changes, and nerve conduction disorders occur due to insufficient claudin production. Claudin is involved in the maintenance of cell polarity due to its apical location in the cell. When pathological processes occur, claudin may undergo phosphorylation, leading to changes in cell polarity and impaired regulation of APC levels. Irritable bowel syndrome is one of the possible causes of impaired regulation of claudin levels. In this pathology there is adecrease in claudin-1 expression. In addition, claudins play different roles in different tumour tissues, and the same protein may be differentially expressed in different forms of cancer. Claudin-4 expression is upregulated as disease progresses in colorectal cancer (CRC), oesophageal squamous cell carcinoma, and its upregulation is associated with decreased invasiveness and metastatic potential, which is positively correlated with improved prognosis. In contrast, overexpression of CLDN 4 in breast cancer (BC) and pancreatic cancer (PC) is positively correlated with invasion, metastasis, angiogenesis and poor prognosis. Aim: systematisation of available data on the biological role and clinical significance of claudin. Materials: review of Russian and foreign literature from 2013-2023.
About the Authors
A. I. Khavkin
Research Clinical Institute of Childhood of the Moscow Region
Russian Federation
Russian Federation
M. O. Tsepilova
St. Petersburg State Pediatric Medical University
Russian Federation
Russian Federation
References
1. Lal-Nag M., Morin P. J. The claudins. Genome Biol. 2009 Aug 26;10:235. doi: 10.1186/gb-2009-10-8-235.
2. Sugawara T., Iwamoto N., Akashi M., Kojima T., Hisatsune J., Sugai M., Furuse M. Tight junction dysfunction in the stratum granulosum leads to aberrant stratum corneum barrier function in claudin-1-deficient mice. J Dermatol Sci. 2013 Apr;70(1):12-8. doi: 10.1016/j.jdermsci.2013.01.002.
3. Ivashkin V., Poluektov Y., Kogan E. et al. Disruption of the pro-inflammatory, anti-inflammatory cytokines and tight junction proteins expression, associated with changes of the composition of the gut microbiota in patients with irritable bowel syndrome. PLoS One. 2021 Jun 11;16(6): e0252930. doi: 10.1371/journal.pone.0252930.
4. Thuijls G., DerikxJ. P., de HaanJ. J. et al. Urine-based detection of intestinal tight junction loss. J Clin Gastroenterol. 2010 Jan;44(1): e14-9. doi: 10.1097/MCG.0b013e31819f5652.
5. WoutersM. M., Vicario M., Santos J.The role of mast cells in functional GI disorders. Gut. 2016. Jan;65(1):155-68. doi: 10.1136/gutjnl-2015-309151.
6. Choghakhori R., Abbasnezhad A., Hasanvand A., AmaniR. Inflammatory cytokines and oxidative stress biomarkers in irritable bowel syndrome: Association with digestive symptoms and quality of life. Cytokine. 2017. May; 93:34-43. doi: 10.1016/j.cyto.2017.05.005.
7. Barbalho S. M., Goulart R. A., Araújo A. C., Guiguer É. L., Bechara M. D. Irritable bowel syndrome: areview of the general aspects and the potential role of vitamin D.Expert Rev Gastroenterol Hepatol. 2019;13(4):345-359. doi: 10.1080/17474124.2019.1570137.
8. Liu J. X., Wei Z. Y., Chen J. S., Lu H. C., Hao L., Li W. J. Prognostic and clinical significance of claudin-4 in gastric cancer: ameta-analysis. World J Surg Oncol. 2015 Jun 25;13:207. doi: 10.1186/s12957-015-0626-2.
9. Resnick M. B., Gavilanez M., Newton E. et al. Claudin expression in gastric adenocarcinomas: atissue microarray study with prognostic correlation. Hum Pathol. 2005 Aug;36(8):886-92. doi: 10.1016/j.humpath.2005.05.019.
10. Wu J., Gao F., Xu T. et al. CLDN1 induces autophagy to promote proliferation and metastasis of esophageal squamous carcinoma through AMPK/STAT1/ULK1 signaling. J Cell Physiol. 2020 Mar; 235(3):2245-59. doi: 10.1002/jcp.29133.
11. Wang D. W., Zhang W. H., Danil G., Yang K., Hu J. K. The role and mechanism of claudins in cancer. Front Oncol. 2022 Dec 22;12:1051497. doi: 10.3389/fonc.2022.1051497.
12. Jung H., Jun K. H., Jung J. H., Chin H. M., Park W. B. The expression of claudin-1, claudin-2, claudin-3, and claudin-4 in gastric cancer tissue. J Surg Res. 2011 May 15;167(2): e185-91. doi: 10.1016/j.jss.2010.02.010.
13. Resnick M. B., Gavilanez M., Newton E. et al. Claudin expression in gastric adenocarcinomas: atissue microarray study with prognostic correlation. Hum Pathol. 2005 Aug;36(8):886-92. doi: 10.1016/j.humpath.2005.05.019.
14. Kwon M. J., Kim S. H., Jeong H. M. et al. Claudin-4 overexpression is associated with epigenetic derepression in gastric carcinoma. Lab Invest. 2011 Nov;91(11):1652-67. doi: 10.1038/labinvest.2011.117.
15. Wang C., WuN., Pei B., MaX., Yang W. Claudin and pancreatic cancer. Front Oncol. 2023 Mar 7;13:1136227. doi: 10.3389/fonc.2023.1136227.
16. Liu M., Yang J., Zhang Y. et al. ZIP4 Promotes Pancreatic Cancer Progression by Repressing ZO-1 and Claudin-1 through aZEB1-Dependent Transcriptional Mechanism. Clin Cancer Res. 2018 Jul 1;24(13):3186-3196. doi: 10.1158/1078-0432.CCR-18-0263.
17. Wang C., Wu N., Pei B., MaX., Yang W. Claudin and pancreatic cancer. Front Oncol. 2023 Mar 7;13:1136227. doi: 10.3389/fonc.2023.1136227.
18. Bertiaux-Vandaële N., YoumbaS. B., Belmonte L., Lecleire S., Antonietti M., Gourcerol G. The expression and the cellular distribution of the tight junctionproteins are altered in irritable bowel syndrome patients with differences according to the disease subtype. Am J Gastroenterol. 2011 Mar 14;106(12):2165-73. doi: 10.1038/ajg.2011.257.
19. Zhang Y., Fang Y., MaL., XuJ., LvC., Deng L., Zhu G. LINC00857 regulated by ZNF460 enhances the expression of CLDN12 by sponging miR-150-5p and recruiting SRSF1 for alternative splicing to promote epithelial-mesenchymal transformation of pancreatic adenocarcinoma cells. RNA Biol. 2022 Dec;19(1):548-559. doi: 10.1080/15476286.2021.1992995.
20. Kolokytha P., Yiannou P., Keramopoulos D., Kolokythas A., Nonni A., Patsouris E., Pavlakis K. Claudin-3 and claudin-4: distinct prognostic significance in triple-negative and luminal breast cancer. Appl Immunohistochem Mol Morphol. 2014;22(2):125-31. doi: 10.1097/PAI.0b013e31828d9d62.
21. Lu S., Singh K., Mangray S., Tavares R., Noble L., ResnickM. B., Yakirevich E. Claudin expression in high-grade invasive ductal carcinoma of the breast: correlation with the molecular subtype. Mod Pathol. 2013 Apr;26(4):485-95. doi: 10.1038/modpathol.2012.187.
22. Fatima Z., RiazS. K., KhanJ. S., Haq F., MalikM. F.A. Dysregulated claudin expression significantly effect breast cancer disease progression. J Cancer Res Ther. 2022 Oct-Dec;18(6):1771-1775. doi: 10.4103/jcrt.JCRT_427_20.
23. Ismagilov A. H., Khuzina D. R., Vanesyan A. S., Zaitseva V. V. The role of biomarkers in the early diagnosis of breast cancer. Tumors of the female reproductive system. 2020;16(4):35-40. (In Russ.) doi: 10.17650/1994-4098-2020-16-4-35-40.@@ Исмагилов А. Х., Хузина Д. Р., Ванесян А. С., Зайцева В. В. Роль биомаркеров вранней диагностике рака молочной железы. Опухоли женской репродуктивной системы. 2020;16(4):35-40. doi: 10.17650/1994-4098-2020-16-4-35-40.
24. Molchanov O. E., Maystrenko D. N., Stanzhevskii A. A. Theranostics of triple negative breast cancer: areview. Diagnostic radiology and radiotherapy. 2023;14(2):15-30. (In Russ.) doi: 10.22328/2079-5343-2023-14-2-15-30.@@ Молчанов О. Е., Майстренко Д. Н., Станжевский А. А. Тераностика трижды негативного рака молочной железы: обзор. Лучевая диагностика итерапия. 2023;14(2):15-30. doi: 10.22328/2079-5343-2023-14-2-15-30.
25. Popova O. P., Kuznetsova A. V., Bogomazova S.Yu., Ivanov A. A. Is there a“low-claudine” phenotype of breast cancer? Archive of pathology. 2022;84(1):45-49. (In Russ.) doi: 10.17116/patol20228401145.@@ Попова О. П., Кузнецова А. В., Богомазова С. Ю., Иванов А. А. Существует ли «низкоклаудиновый» фенотип рака молочной железы? Архив патологии. 2022;84(1):45-49. doi: 10.17116/patol20228401145.
Review
For citations:
Khavkin A.I., Tsepilova M.O. Claudin is a promising biomarker of intestinal wall permeability. Archives of Pediatrics and Pediatric Surgery. 2024;2(2):76-79. (In Russ.) https://doi.org/10.31146/2949-4664-apps-2-2-76-79
Views:
86
Email this article 